biotech

The biotech industry is chipping away at the obstacles standing between the lab and the dinner plate.

Scientific advances almost always have the potential to benefit human lives. In times like these, they have the power to save them.

The COVID-19 pandemic is still with us. Biomedical innovation has rallied to address that pressing concern while continuing to tackle broader research challenges.

The makers of the CRISPR-based testing platform, called miSHERLOCK, say it could enable people at home or physicians in resource-limited environments to detect SARS-CoV-2—and eventually, other pathogens.

The masks contain freeze-dried, cell-free biosensors, enabling them to detect pathogens including SARS-CoV-2.

Tired of dancing to the tunes of international funders, and doubtful that long-promised national grants will come, a handful of African biomedical scientists have turned to private investors to bankroll their dreams of autonomy in the lab.

Scientifically groundless regulations could undercut the potential of gene-edited crops, much as they have with GMOs.

A nascent but growing consumer market for brain-computer interface technology is driving the development of sleek new tools for decoding brain activity.

The California-based company Humm has developed a “bioelectric memory patch” to improve working memory, but some experts question the efficacy of the device.

In a small trial of deceased volunteers, a Seattle-based company called Recompose demonstrates that its method for “natural organic reduction” of a human body completely breaks down soft tissue.

The midwestern state has quietly laid the groundwork for a biotech hub.

The physician-researcher laid the groundwork for genetic cloning and led the US Food and Drug Administration as the country faced the AIDS crisis in the 1980s.

The US Food and Drug Administration halts a study by Solid Biosciences after a patient experiences severe side effects following treatment.

A device implanted into mice can modulate brain circuit activity over long periods of time.

Unlike biotech tools adapted from nature, the invention was entirely conceived by humans and represents one of the few proteins made from scratch in the lab.

Executives at a biotech that develops new antibodies argue that Ram Sasisekharan didn’t come up with the structures for at least two experimental therapies that his group has described.

The pharmaceutical industry is looking to machine learning to overcome complex challenges in drug development.